Skip to main content
SpringerLink
Log in

Strategies for Improving Quality of Life in Older Patients with Metastatic Breast Cancer

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Given both the increase in the mean age of the population of Western countries and the high incidence of breast cancer beyond the age of 65 years, it is evident that breast cancer in older women will be a very common problem for the medical oncologist. Metastatic breast cancer is still not amenable to a cure; therefore quality of life during therapy is an important issue, which until recently has been poorly investigated. Similarly, despite recent advances in breast cancer therapy, physicians have been reluctant to enrol older patients in clinical trials, and there is a lack of data regarding this population. This review focuses on quality-of-life issues during metastatic breast cancer treatment in geriatric patients, comparing the standard therapeutic options and newer approaches. Although first-line endocrine therapy with tamoxifen remains a standard treatment, the newer third-generation aromatase inhibitors provide similar or better efficacy with fewer adverse effects and a better quality of life. It has been a common belief that chemotherapy impairs quality of life, but recent studies in advanced breast cancer have shown that this therapy has a positive effect on quality of life, at least in responders. Consequently, chemotherapy should not be denied to elderly patients with metastatic breast cancer, provided a prior geriatric assessment is performed to evaluate the risk-benefit ratio. New chemotherapy strategies, such as the taxanes and orally administered chemotherapy, represent a very attractive alternative for a better quality of life in elderly patients with metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Anderson RN. United States life tables, 1997 [online]. Available from URL: http://www.cdc.gov/nchs/data/nvs47_28.pdf [Accessed 2001 Aug 24]

  2. Kimmick G, Muss HB. Breast cancer in older women. Clin Geriatr Med 1997 May; 13(2): 265–82

    PubMed  CAS  Google Scholar 

  3. Kimmick GG, Balducci L. Breast cancer and aging. Clinical interactions. Hematol Oncol Clin North Am 2000 Feb; 14(1): 213–34

    Article  PubMed  CAS  Google Scholar 

  4. Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery and survival. Cancer 1989 Mar 1; 63: 976–81

    Article  PubMed  CAS  Google Scholar 

  5. Harlacher R, Fusgen I. Geriatric assessment in the elderly cancer patients. J Cancer Res Clin Oncol 2000 Jul; 126(7): 369–74

    Article  PubMed  CAS  Google Scholar 

  6. Tsevat J, Cook EF, Green ML, et al. Health values of the seriously ill. Arch Intern Med 1994; 122: 514–20

    Google Scholar 

  7. McKenna Sr RJ. Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up. Cancer 1994 Oct 1; 74(7 Suppl.): 2107–17

    Article  PubMed  Google Scholar 

  8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in Oncology. J Natl Cancer Inst 1993 Mar3; 85(5): 365–76

    Article  PubMed  CAS  Google Scholar 

  9. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997 Mar; 15(3): 974–86

    PubMed  CAS  Google Scholar 

  10. McLachlan SA, Devins GM, Goodwin P. Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer 1998 Mar; 34(4): 510–7

    Article  PubMed  CAS  Google Scholar 

  11. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000 Feb; 14(1): 63–77

    Article  PubMed  CAS  Google Scholar 

  12. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 2000 Nov; 14(11A): 221–7

    CAS  Google Scholar 

  13. Chang J, Clark GM, Allred D, et al. Survival of metastatic breast cancer patients: importance of initial prognosis markers in 654 patients. Presented at 37th annual meeting of the American Society of Clinical Oncology: 2001 May 12–15, San Francisco (CA)

  14. Ries LAG, Henson DE, Harras A. Survival from breast cancer according to tumor size and nodal status. Surg Oncol Clin North Am 1994; 3: 35

    Google Scholar 

  15. Mor V. QOL measurement scales for cancer patients: differentiating effects of age from effects of illness. Oncology(Huntingt) 1992 Feb; 6Suppl. 2: 146–52

    CAS  Google Scholar 

  16. Balducci L, Extermann M. Cancer chemotherapy in the older patient. What the medical oncologist needs to know. Cancer 1997 Oct; 80(7): 1317–22

    Article  PubMed  CAS  Google Scholar 

  17. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994 Jan 15; 120(2): 104–10

    PubMed  CAS  Google Scholar 

  18. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000; 36: 1741–54

    Article  PubMed  CAS  Google Scholar 

  19. Schagen SB, van Dam FSAM, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999 Feb 1; 85(3): 640–50

    Article  PubMed  CAS  Google Scholar 

  20. Conroy T, Mercier M, Bonneterre J, et al. Comparison of quality of life cancer-specific instruments: FACT-G, EORTC QLQ-C30 and FLIC. Presented at 37th annual meeting of the American Society of Clinical Oncology: 2001 May 12–5: San Francisco (CA)

  21. Curran D, Aaronson N, Standaert B, et al. Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study Eur J Cancer 2000; 36: 834–44

    Article  PubMed  CAS  Google Scholar 

  22. Kornblith AB, Hollis DR, Zuckerman E, et al. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol 1993 Nov; 11(11): 2081–9

    PubMed  CAS  Google Scholar 

  23. Haqamies-Blomqvist L, Luoma M-L, Sjöström J, et al. Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group. Eur J Cancer 2000; 36: 1411–7

    Article  Google Scholar 

  24. Kramer JA, Curran D, Piccart MJ, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 2000; 36: 1498–506

    Article  PubMed  CAS  Google Scholar 

  25. Neuberg D, Fetting J, Sledge Jr GW, et al. Changes in quality of life (QOL) during induction therapy in patients enrolled in a randomized trial of adriamycin, taxol, and adriamycin plus taxol in metastatic breast cancer. Presented at 33rd annual meeting of the American Society of Clinical Oncology: 1997 May 12–15: Denver (CO)

  26. Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999 May; 55(2): 188–99

    Article  Google Scholar 

  27. Balducci L. Perspectives on quality of life in older patients with cancer. Drugs Aging 1994 Apr; 4(4): 313–24

    Article  PubMed  CAS  Google Scholar 

  28. Ganz PA. Breast cancer in older women: quality-of-life considerations. Cancer Control 1994 Jul–Aug; 1(4): 372–9

    PubMed  Google Scholar 

  29. Coates A, Genski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 1992 Dec; 10(12): 1833–8

    PubMed  CAS  Google Scholar 

  30. Coates AS, Hurny C, Peterson HF, et al. Quality of life scores predict outcome in metastatic but not in early breast cancer. International Breast Cancer Study Group. J Clin Oncol 2000 Nov 15; 18(22): 3768–74

    PubMed  CAS  Google Scholar 

  31. Shimozuma K, Sonoo H, Ichihara K, et al. The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 2000; 30(3): 255–61

    Article  PubMed  CAS  Google Scholar 

  32. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifenas first-line therapy for advanced breast cancer in 668 post-menopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol Nov 15; 18(22): 3748–57

  33. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: results of a North-American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000 Nov 15; 18(22): 3758–67

    PubMed  CAS  Google Scholar 

  34. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001 May 15; 19(10): 2596–606

    PubMed  CAS  Google Scholar 

  35. Thurlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1997; 33(7): 1017–24

    Article  PubMed  CAS  Google Scholar 

  36. Rose C, Freue M, Kjaer M, et al. Anopen, comparative randomized trial comparing formestane vs megestrol acetate as a second line therapy in post menopausal advanced breast cancer patients [abstract]. Presented at the 7th EORTC Breast Cancer Working Conference: 1996 Sep 10–13: Bordeaux

  37. Bernhard J, Castiglione-Gertsch M, Schmitz SF, et al. Quality of life in post-menopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1999 Jun; 35(6): 913–20

    Article  PubMed  CAS  Google Scholar 

  38. Venturino A, Comandini D, Granetto C, et al. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability. Breast Cancer Res Treat 2000 Aug; 62(3): 217–22

    Article  PubMed  CAS  Google Scholar 

  39. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000 Apr; 18(7): 1399–411

    PubMed  CAS  Google Scholar 

  40. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in post-menopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000 May; 36(8): 976–82

    Article  PubMed  CAS  Google Scholar 

  41. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997 Feb 15; 79(4): 730–9

    Article  PubMed  CAS  Google Scholar 

  42. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new aromatase inhibitor for advanced breast cancer: double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998 Feb; 16(2): 453–61

    PubMed  CAS  Google Scholar 

  43. Buzdar A, Douma J, Davidson N, et al. Phase III multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001 Jul 15; 19(14): 3357–66

    PubMed  CAS  Google Scholar 

  44. Goss PE, Winer EP, Tannock IF, et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol 1999 Jan; 17(1): 52–63

    PubMed  CAS  Google Scholar 

  45. Beller E, Tattersall M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 1997 Mar; 8(3): 277–83

    Article  PubMed  CAS  Google Scholar 

  46. Wiseman LR, Goa K. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996 Oct; 9(4): 292–306

    Article  PubMed  CAS  Google Scholar 

  47. Bernhard J, Thurlimann B, Schmitz SF, et al. Defining clinical benefit in postmenopausal patients with breast cancer under second-line treatment: does quality of life matter? J Clin Oncol 1999 Jun; 17(6): 1672–9

    PubMed  CAS  Google Scholar 

  48. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998 Sep 15; 83(6): 1142–52

    Article  PubMed  CAS  Google Scholar 

  49. Piotrovsky VK, Huang ML, Van Peer A, et al. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and breast cancer patients. Cancer Chemother Pharmacol 1998; 42: 221–8

    Article  PubMed  CAS  Google Scholar 

  50. Dranitsaris G, Leung P, Mather J, et al. Cost-utility of secondline hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 2000 Aug; 11(7): 591–601

    Article  PubMed  CAS  Google Scholar 

  51. Du X, Goodwin JS. Patterns of use of chemotherapy for breast ancer in older women: findings from Medicare claims data. J Clin Oncol 2001 Mar 1; 19(5): 1455–61

    PubMed  CAS  Google Scholar 

  52. Kimmick GG, Fleming R, Muss HB, et al. Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging 1997 Jan; 10(1): 34–49

    Article  PubMed  CAS  Google Scholar 

  53. Stockler M, Wilcken NR, Ghersi D, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000 Jun; 26(3): 151–68

    Article  PubMed  CAS  Google Scholar 

  54. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987 Dec 10; 317: 1490–5

    Article  PubMed  CAS  Google Scholar 

  55. Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988 Sep; 6(9): 1377–87

    PubMed  CAS  Google Scholar 

  56. Ramirez AJ, Towlson KE, Leaning MS, et al. Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 1998 Dec; 78(11): 1488–94

    Article  PubMed  CAS  Google Scholar 

  57. Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000 Jun; 18(12): 2395–405

    PubMed  CAS  Google Scholar 

  58. Extermann M, Zanetta S, Chen H, et al. Are older French patients as willing as older American patients to undertake chemotherapy? Presented at 37th annual meeting of the American Society of Clinical Oncology: 2001 May 12–15: San Francisco (CA)

  59. Balducci L, Hardy CL, Lyman GH. Hematopoietic reserve in the older cancer patient: clinical and economical considerations. Cancer Control Nov–Dec 2000; 7(6): 539–47

    CAS  Google Scholar 

  60. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group trial VII. J Clin Oncol 2000 Apr; 18(7): 1412–22

    PubMed  CAS  Google Scholar 

  61. Dees EC, O’Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18(6): 521–9

    Article  PubMed  CAS  Google Scholar 

  62. Gelman RS, Taylor IV SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984: 2: 1404–13

    PubMed  CAS  Google Scholar 

  63. Taylor IV SG, Gelman RS, Falkson G, et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986 Apr; 104(4): 455–61

    PubMed  Google Scholar 

  64. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 1992 Jul 1; 268(1): 57–62

    Article  PubMed  CAS  Google Scholar 

  65. Ibrahim NK, Buzdar AU, Asmar L, et al. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the MD Anderson experience, with long-term follow-up. Ann Oncol 2000 Dec; 11(12): 1597–601

    Article  PubMed  CAS  Google Scholar 

  66. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 2001 Mar–Apr; 8(2 Suppl.): 1–25

    PubMed  CAS  Google Scholar 

  67. Bontenbal M, Andersson M, Wildiers J, et al. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer 1998 Jun; 77(12): 2257–63

    Article  PubMed  CAS  Google Scholar 

  68. Hortobagyi GN, Yap HY, Kau SW, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 1989 Feb; 12(1): 57–62

    Article  PubMed  CAS  Google Scholar 

  69. Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995 Feb; 22 (1 Suppl. 1): 11–3

    PubMed  CAS  Google Scholar 

  70. Perez EA, Vogel CL, Irwin DH, et al. Comparative efficacy and toxicity of weekly paclitaxel in women age ≥65 and age < 65 with metastatic breast cancer (MBC). Presented at 37th annual meeting of the American Society of Clinical Oncology: 2001 May 12–15: San Francisco (CA)

  71. Hainsworth JD, Burris III HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a minnie pearl cancer research network phase II trial. J Clin Oncol 2001 Aug; 19(15): 3500–5

    PubMed  CAS  Google Scholar 

  72. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33: 301–3

    Article  PubMed  CAS  Google Scholar 

  73. Vogel C, O’Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999 Apr; 10: 397–402

    Article  PubMed  CAS  Google Scholar 

  74. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 Jun; 15(6): 2403–13

    PubMed  CAS  Google Scholar 

  75. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995 Nov; 13(11): 2731–6

    PubMed  CAS  Google Scholar 

  76. Ranson MR, Carmichael J, O’Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997 Oct; 15(10): 3185–91

    PubMed  CAS  Google Scholar 

  77. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 2000 Sep 1; 89(5): 1037–47

    Article  PubMed  CAS  Google Scholar 

  78. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997 Jan; 15(1): 110–5

    PubMed  CAS  Google Scholar 

  79. Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 2001 Feb; 35(2): 217–27

    Article  PubMed  CAS  Google Scholar 

  80. Hortobagyi GN, Ibrahim N, Young R, et al. A study of UFT + leucovorin given as a twice daily regimen in the treatment of patients (pts) with previously treated metastatic breast cancer (mbc). Presented at 37th annual meeting of the American Society of Clinical Oncology: 2001 May 12–15: San Francisco (CA)

  81. Villalon AH, de Guzman LB, Samson MC, et al. A randomized trial of oral UFT (tegafur + uracil) and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer at Philippine General Hospital. Presented at 33rd annual meeting of the American Society of Clinical Oncology: 1997 May 12–15 Denver (CO)

  82. Sun W, Haller D. UFT in the treatment of colorectal and breast cancer. Oncology (Huntingt) 2001 Jan; 15Suppl. 2: 49–56

    CAS  Google Scholar 

  83. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999 Feb; 17: 485–93

    PubMed  CAS  Google Scholar 

  84. O’Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda− (capecitabine) vs CMF as first-line chemotherapy in women aged ≥55 years [abstract]. Presented at 34th annual meeting of the American Society of Clinical Oncology: May 16–19 1998; Los Angeles (CA)

  85. Lasota WS, de Valeriola DL, Piccart MJ. Potential role of oral anthracyclines in older patients with cancer. Drugs Aging 1994 May; 4(5): 392–402

    Article  PubMed  CAS  Google Scholar 

  86. Kurtz JE, Deplanque G, Borel C, et al. Dose-finding of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. Ann Oncol 2000; 11(2): 229–30

    Article  PubMed  CAS  Google Scholar 

  87. Chevallier B, Monnier A, Metz R, et al. Phase II study of oral idarubicin in elderly patients with metastatic breast cancer. Am J Clin Oncol 1990; 13(5): 436–9

    Article  PubMed  CAS  Google Scholar 

  88. Toffoli G, Crivellari D, Magri MD, et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Cancer Res 2000 Jun; 6(6): 2279–87

    PubMed  CAS  Google Scholar 

  89. Leonard RC, Cameron DA, Anderson A, et al. Idarubicin and cyclophosphamide — an active oral chemotherapy regimen for advanced breast cancer. Crit Rev Oncol Hematol 2000 Jan; 33(1): 61–6

    Article  PubMed  CAS  Google Scholar 

  90. Zaniboni A, Bolognesi A, Arnoldi E, et al. Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. Anticancer Drugs 1998; 9(4): 295–9

    Article  PubMed  CAS  Google Scholar 

  91. Trillet-Lenoir V, Delozier M, Lichinister M, et al. A phase II study of oral vinorelbine (NVBo) in first-line locally advanced/metastatic breast cancer (ABC) chemotherapy: Preliminary results. Presented at 37th annual meeting of the American Society of Clinical Oncology: 2001 May 12–15: San Francisco (CA)

  92. Vogel C, Cobleigh MA, Tripathy D, et al. First-line, single agent Herceptin® (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001; 37: S25–9

    Article  PubMed  CAS  Google Scholar 

  93. Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol 1999 Aug; 26Suppl. 12: 84–8

    PubMed  CAS  Google Scholar 

  94. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her23 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001 Mar 15; 344: 783–92

    Article  PubMed  CAS  Google Scholar 

  95. Zachariah B, Balducci L, Venkattaramanabalaji GV, et al. Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side-effects. Int J Radiat Oncol Biol Phys 1997 Dec1; 39(5): 1125–9

    Article  PubMed  CAS  Google Scholar 

  96. Baziotis N, Yakoumanis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998 Sep–Oct; 55(5): 377–81

    Article  PubMed  CAS  Google Scholar 

  97. Fuster D, Herranz D, Vidal-Sicart S, et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer. Nucl Med Commun 2000 Jul; 21(7): 623–6

    Article  PubMed  CAS  Google Scholar 

  98. Bosnjak S, Radulovic S, Neskovic-Konstantinovic Z, et al. Patient statement of satisfaction with antiemetic treatment is related to quality of life. Am J Clin Oncol 2000 Dec; 23(6): 575–8

    Article  PubMed  CAS  Google Scholar 

  99. Kobayashi K, Ishihara Y, Nukariya N, et al. Effects of antiemetic drug (tropisetron) on quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicenter study. Respirology 1999; 4: 229–38

    Article  PubMed  CAS  Google Scholar 

  100. De Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perception of the side effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76(8): 1055–61

    Article  PubMed  Google Scholar 

  101. Passik SD, Kirsh KL, Rosenfeld B, et al. The changeable nature of patients’ fears regarding chemotherapy: implications for palliative care. J Pain Symptom Manage 2001 Feb; 21(2): 113–20

    Article  PubMed  CAS  Google Scholar 

  102. Kimmick GG, Muss HB. Systemic therapy for older women with breast cancer. Oncology (Huntingt) 2001 Mar; 15(3): 280–91

    CAS  Google Scholar 

  103. Hensley ML, Schuchter ML, Lindley C,et al. American Society of Clinical Oncology clinical practices guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999 Oct; 17(10): 3333–55

    PubMed  CAS  Google Scholar 

  104. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000 Mar; 18(6): 1378–91

    PubMed  CAS  Google Scholar 

  105. Crome P. Pain relief. In: Crome P, Ford G, editors. Drugs and the older population. London: Imperial College Press, 2000: 580–600

    Chapter  Google Scholar 

  106. Gloth III FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001; 49: 188–99

    Article  PubMed  Google Scholar 

  107. Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy induced alopecia using an effective scalp cooling system. Eur J Cancer 2000; 36: 766–71

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge help from Laboratoire Sanofi-Synthélabo France for bibliographical assistance. The authors have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, 1 Av Molière, Strasbourg, 670980, France

    Jean-Emmanuel Kurtz & Patrick Dufour

Authors
  1. Jean-Emmanuel Kurtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Emmanuel Kurtz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurtz, JE., Dufour, P. Strategies for Improving Quality of Life in Older Patients with Metastatic Breast Cancer. Drugs Aging 19, 605–622 (2002). https://doi.org/10.2165/00002512-200219080-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219080-00006

Keywords

Search

Navigation